Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A.
Pennell DJ, et al.
Haematologica. 2012 Jun;97(6):842-8. doi: 10.3324/haematol.2011.049957. Epub 2012 Jan 22.
Haematologica. 2012.
PMID: 22271905
Free PMC article.
Clinical Trial.